Search
Abivax SA
ABVXAdd to Watchlist
144.650USD
+12.090+9.12%
Close 07/02, 13:00（ET）Quotes delayed by 15 min
0.00Market Cap
--P/E TTM
More Details of Abivax SA Company
Abivax SA is a clinical stage biopharmaceutical company focusing on the discovery, development and commercialization of anti-viral compounds and therapeutic vaccines against severe and life threatening infectious diseases. ABIVAX utilizes RNA-protein interaction interference and cytotoxic TH1 cell amplification to generate therapies to help patients clear viruses like HIV, HBV and HPV. The Company's product pipeline comprises ABX 203, which is the therapeutic vaccine candidate obtained from the Centre for Genetic Engineering and Biotechnology, Cuba (CIGB) and is intended for patients with chronic hepatitis B disease; and ABX196, the adjuvant for therapeutic vaccines, among others.
Abivax SA Info
Ticker SymbolABVX
Company nameAbivax SA
IPO dateJun 26, 2015
CEOde Garidel (Marc)
Number of employees- -
Security typeDepository Receipt
Fiscal year-end- -
Address7-11 Boulevard Haussmann
CityPARIS
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryFrance
Postal code75009
Phone33153830963
Websitehttps://www.abivax.com/
Ticker SymbolABVX
IPO dateJun 26, 2015
CEOde Garidel (Marc)
Company Executives of Abivax SA
Name
Name/Position
Position
Shareholding
Change
Mr. Pierre Courteille
Mr. Pierre Courteille
Chief Business Officer
Chief Business Officer
--
--
Mr. Didier Scherrer, Ph.D.
Mr. Didier Scherrer, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Mr. Didier Bruno Blondel
Mr. Didier Bruno Blondel
Chief Financial Officer, Executive Vice President, Non-Member Secretary of the Board of Directors
Chief Financial Officer, Executive Vice President, Non-Member Secretary of the Board of Directors
--
--
Ms. Corinna Zur Bonsen-Thomas
Ms. Corinna Zur Bonsen-Thomas
Independent Director
Independent Director
--
--
Mr. Kinam Hong
Mr. Kinam Hong
Director, Representative of Sofinnova Partners
Director, Representative of Sofinnova Partners
--
--
Mr. Jerome Denis, Ph.D.
Mr. Jerome Denis, Ph.D.
Executive Vice President - Process Development & Manufacturing
Executive Vice President - Process Development & Manufacturing
--
--
Mr. Marc de Garidel
Mr. Marc de Garidel
Chief Executive Officer
Chief Executive Officer
--
--
Ms. Ida Hatoum
Ms. Ida Hatoum
Chief People Officer, Chief Compliance Officer
Chief People Officer, Chief Compliance Officer
--
--
Dr. June H. Lee, M.D.
Dr. June H. Lee, M.D.
Independent Director
Independent Director
--
--
Mr. Troy A. Ignelzi
Mr. Troy A. Ignelzi
Independent Director
Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Pierre Courteille
Mr. Pierre Courteille
Chief Business Officer
Chief Business Officer
--
--
Mr. Didier Scherrer, Ph.D.
Mr. Didier Scherrer, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Mr. Didier Bruno Blondel
Mr. Didier Bruno Blondel
Chief Financial Officer, Executive Vice President, Non-Member Secretary of the Board of Directors
Chief Financial Officer, Executive Vice President, Non-Member Secretary of the Board of Directors
--
--
Ms. Corinna Zur Bonsen-Thomas
Ms. Corinna Zur Bonsen-Thomas
Independent Director
Independent Director
--
--
Mr. Kinam Hong
Mr. Kinam Hong
Director, Representative of Sofinnova Partners
Director, Representative of Sofinnova Partners
--
--
Mr. Jerome Denis, Ph.D.
Mr. Jerome Denis, Ph.D.
Executive Vice President - Process Development & Manufacturing
Executive Vice President - Process Development & Manufacturing
--
--
FAQs
Who are the top five shareholders of Abivax SA?
The top five shareholders of Abivax SA are: Mr. Pierre Courteille
How many institutions hold shares of Abivax SA (ABVX)?
As of 2026Q1, 353 institutions hold shares of Abivax SA, with a combined market value of approximately 61.40M, accounting for 78.18% of the total shares. Compared to 2025Q4, institutional shareholding has increased by -289711.00.